文献速递慢阻肺

Clara细胞分泌蛋白(CC-16)对慢阻肺风险与进展的保护作用:孟德尔随机化研究

Protective effect of club cell secretory protein (CC-16) on COPD risk and progression: a Mendelian randomisation study.
PubMed 文献 · Thorax · 2020-08-24

研究对两个慢阻肺队列(LHS n=3850,ECLIPSE n=1702)进行血清CC-16全基因组关联荟萃分析,鉴定7个独立相关SNP(6个为新发现)。以这些SNP为工具变量行孟德尔随机化分析,提示血清CC-16升高对慢阻肺风险(MR估计-0.11,SE 0.04,p=0.008)和进展(仅LHS,MR估计7.40,SE 3.28,p=0.02)有保护性因果效应。

要点

  • 血清CC-16升高可能降低慢阻肺患病风险(MR估计-0.11,p=0.008)。
  • 血清CC-16升高可能与FEV1年下降减缓相关(仅LHS,p=0.02)。
  • 7个CC-16相关SNP中6个为新发现,5个与肺组织基因表达相关。

核心结论

  • 血清CC-16水平对慢阻肺风险及进展可能存在保护性因果效应,生物学基础待进一步研究。

研究设计与样本

  • 对LHS(n=3850)和ECLIPSE(n=1702)两个慢阻肺队列行血清CC-16全基因组关联荟萃分析。
  • 以CC-16相关SNP为工具变量行孟德尔随机化分析,评估对慢阻肺风险和进展的因果效应。
  • 慢阻肺风险分析使用国际慢阻肺遗传学联盟/UK-Biobank数据集(35 735例慢阻肺病例,222 076例对照)。
  • 慢阻肺进展定义为LHS和ECLIPSE中FEV1年变化。
  • 利用肺组织表达数量性状位点研究(n=1111)分析SNP与基因表达的关联。

主要发现

  • 鉴定出7个与血清CC-16水平独立相关(p<5×10-8)的SNP,其中6个为新发现。
  • 孟德尔随机化分析提示血清CC-16升高对慢阻肺风险有保护性因果效应(MR估计-0.11,SE 0.04,p=0.008)。
  • 孟德尔随机化分析提示血清CC-16升高对慢阻肺进展有保护性因果效应(仅LHS,MR估计7.40,SE 3.28,p=0.02)。
  • 5个SNP与肺组织多个基因表达相关(错误发现率<0.1),包括编码CC-16的SCGB1A1基因。

关键数值与推荐

  • 7个SNP与血清CC-16独立相关,显著性阈值p<5×10-8。
  • 慢阻肺风险MR估计(SE)为-0.11(0.04),p=0.008。
  • 慢阻肺进展MR估计(SE)为7.40(3.28),p=0.02(仅LHS)。
  • 5个SNP与肺组织基因表达相关,错误发现率<0.1。

临床怎么用

  • 血清CC-16可能作为慢阻肺风险分层和进展监测的潜在生物标志物。
  • CC-16相关遗传变异及SCGB1A1基因表达可为慢阻肺机制研究和靶点探索提供线索。

局限性

  • 孟德尔随机化分析中慢阻肺进展的因果效应仅在LHS队列中显著。
  • 生物学基础尚不明确,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The anti-inflammatory pneumoprotein club cell secretory protein-16 (CC-16) is associated with the clinical expression of chronic obstructive pulmonary disease (COPD). We aimed to determine if there is a causal effect of serum CC-16 level on the risk of having COPD and/or its progression using Mendelian randomisation (MR) analysis. METHODS: We performed a genome-wide association meta-analysis for serum CC-16 in two COPD cohorts (Lung Health Study (LHS), n=3850 and ECLIPSE, n=1702). We then used the CC-16-associated single-nucleotide polymorphisms (SNPs) as instrumental variables in MR analysis to identify a causal effect of serum CC-16 on 'COPD risk' (ie, case status in the International COPD Genetics Consortium/UK-Biobank dataset; n=35 735 COPD cases, n=222 076 controls) and 'COPD progression' (ie, annual change in forced expiratory volume in 1 s in LHS and ECLIPSE). We also determined the associations between SNPs associated with CC-16 and gene expression using n=1111 lung tissue samples from the Lung Expression Quantitative Trait Locus Study. RESULTS: We identified seven SNPs independently associated (p<5×10-8) with serum CC-16 levels; six of these were novel. MR analysis suggested a protective causal effect of increased serum CC-16 on COPD risk (MR estimate (SE) -0.11 (0.04), p=0.008) and progression (LHS only, MR estimate (SE) 7.40 (3.28), p=0.02). Five of the SNPs were also associated with gene expression in lung tissue (at false discovery rate <0.1) of several genes, including the CC-16-encoding gene SCGB1A1. CONCLUSION: We have identified several novel genetic variants associated with serum CC-16 level in COPD cohorts. These genetic associations suggest a potential causal effect of serum CC-16 on the risk of having COPD and its progression, the biological basis of which warrants further investigation.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Milne S, Li X, Hernandez Cordero AI, et al. Protective effect of club cell secretory protein (CC-16) on COPD risk and progression: a Mendelian randomisation study. Thorax. 2020. PMID: 32839289. doi:10.1136/thoraxjnl-2019-214487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。